These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27440209)

  • 21. Meeting report: the Schizophrenia International Research Society (SIRS) South America Conference (August 5-7, 2011).
    Massuda R; Chaves C; Trzesniak C; Machado-de-Sousa JP; Zanetti MV; Murray RM; Gattaz WF; Busatto GF
    Schizophr Res; 2012 May; 137(1-3):1-6. PubMed ID: 22459672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
    Scharfetter J
    Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness.
    Scornaiencki R; Cantrup R; Rushlow WJ; Rajakumar N
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1195-208. PubMed ID: 19275776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focused motor stereotypies do not require enhanced activation of neurons in striosomes.
    Glickstein SB; Schmauss C
    J Comp Neurol; 2004 Feb; 469(2):227-38. PubMed ID: 14694536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats.
    Bubenikova-Valesova V; Svoboda J; Horacek J; Vales K
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):873-83. PubMed ID: 19154630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
    Wilson JM; Ogden AM; Loomis S; Gilmour G; Baucum AJ; Belecky-Adams TL; Merchant KM
    Neuropharmacology; 2015 Dec; 99():379-86. PubMed ID: 26256420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic approaches to cognitive enhancement in schizophrenia.
    Burdick KE; Gopin CB; Malhotra AK
    Harv Rev Psychiatry; 2011; 19(3):102-8. PubMed ID: 21631157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol.
    Mo YQ; Jin XL; Chen YT; Jin GZ; Shi WX
    Neuropsychopharmacology; 2005 Feb; 30(2):261-7. PubMed ID: 15578005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates.
    Meschler JP; Clarkson FA; Mathews PJ; Howlett AC; Madras BK
    J Pharmacol Exp Ther; 2000 Mar; 292(3):952-9. PubMed ID: 10688609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine.
    Gleason SD; Witkin JM
    Psychopharmacology (Berl); 2006 May; 186(1):25-31. PubMed ID: 16575553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 28-April 1, 2015.
    Markota M; Mehta U; Solis M
    Clin Schizophr Relat Psychoses; 2015; 9(2):60-4. PubMed ID: 26158792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies.
    Ferrer B; Gorriti MA; Palomino A; Gornemann I; de Diego Y; Bermudez-Silva FJ; Bilbao A; Fernandez-Espejo E; Moratalla R; Navarro M; Rodríguez de Fonseca F
    Eur J Pharmacol; 2007 Mar; 559(2-3):180-3. PubMed ID: 17291487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.